Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

NCT03778229 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

367

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma

Interventions

DRUG: osimertinib
DRUG: savolitinib
DRUG: placebo

Sponsor

AstraZeneca

Collaborators

[object Object]